Ortho Clinical Diagnostics announced its VITROS® Anti-SARS-CoV-2 IgG Quantitative Test is the first quantitative COVID-19 IgG antibody test to receive U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA). Ortho's new quantitative COVID-19 IgG antibody test targets the S1 spike protein and is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2. The test offers 100% specificity and excellent sensitivity. The new test is calibrated to the World Health Organization (WHO) International Standard2 for anti-SARS-CoV-2 IgG antibodies, which gives clinicians and public health leaders a standard tool to measure antibody response to SARS-CoV-2. This uniform data is a first step toward understanding the rise and fall of antibodies in individuals and the long-term impacts of the COVID-19 pandemic on communities and the overall population.